David Hogg, MD, FRCPC

Cancer genetics: melanoma and testicular cancer

The primary focus of my laboratory is cancer genetics. In collaboration with Norman Lassam (who tragically died in August, 2000) my laboratory described one of the first families with a germline mutation in the CDKN2A gene (Liu et al., Oncogene, 11: 405-412, 1995).

We went on to establish a program in inherited melanoma. The overall aim of the Toronto melanoma clinic is to utilize progress in cancer genetic research to focus preventative efforts on a population at high risk for this disease. We hypothesize that such directed surveillance will decrease morbidity and mortality from melanoma in the families and individuals under our care.

The Toronto melanoma program now comprises a clinic to identify and counsel families at risk; a clinical genetic laboratory dedicated to CDKN2A mutation testing; and a basic science program to characterize other genes that predispose to melanoma.

The clinic's multidisciplinary staff includes oncologists, dermatologists, nursing staff, plastic surgeons, a medical geneticist and social workers. Over the past four years, we have accrued over 200 melanoma families and have screened 170 of these kindreds for CDKN2A mutations (Liu et al., Nat Genet, 21: 128-132, 1999). We have also determined that a significant number of patients with multiple primary melanomas carry such mutations (Monzon et al., New Engl J Med, 338: 879-887, 1998).

My second major area of interest is the genetic basis of inherited and sporadic testicular germ cell cancer (Peng et al., Cancer Res, 55: 2871-2875, 1995; King et al., Cancer Res, 57: 209-214, 1997). I am also a member of the International Testicular Cancer Mapping Consortium. We recently published the first description of a testicular cancer susceptibility gene mapping to chromosome Xq27 (Rapley et al., Nat Genet, 24:197-200, 2000).
Curr Oncol. 2019 Jun;26(3):e418-e421
Saibil SD, Bonilla L, Majeed H, Sotov V, Hogg D, Chappell MA, Cybulsky M, Butler MO
Sci Rep. 2019 May 14;9(1):7390
Veitch Z, Zer A, Loong H, Salah S, Masood M, Gupta A, Bradbury PA, Hogg D, Wong A, Kandel R, Charames GS, Abdul Razak AR
Cancer. 2019 Feb 15;:
Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL
Cancer Immunol Immunother. 2019 Feb 11;:
Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, Bonilla L, Majeed H, Hogg D, Joshua AM, Crump M, Franke N, Spreafico A, Hansen A, Al-Habeeb A, Leong W, Easson A, Reedijk M, Goldstein DP, McCready D, Yasufuku K, Waddell T, Cypel M, Pierre A,...
Eur J Cancer. 2018 Dec 06;107:1-7
Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A
Lancet Oncol. 2018 Oct 18;:
Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD
Melanoma Res. 2018 Jul 31;:
Nicholas MN, Khoja L, Atenafu EG, Hogg D, Quirt I, Butler M, Joshua AM
Clin Cancer Res. 2018 Jun 14;:
Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, Park M, Guiot MC, Petrecca K, Mihalcioiu C, Watson IR, Siegel PM, Rose AAN
Ann Oncol. 2017 Oct 01;28(10):2581-2587
Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA



Associate Professor, Department of Medical Biophysics, University of Toronto